Baotai Liang

This study is testing whether adding two new drugs (fasudil hydrochloride and a PD1 inhibitor) to standard hormone therapy before prostate cancer surgery works better than standard therapy alone. The goal is to see if this combination shrinks the cancer more effectively, potentia…

This study is testing whether adding a drug called homoharringtonine to standard hormone-blocking therapy can better shrink prostate cancer before surgery. It aims to see if this combination leads to less cancer remaining after surgery and improves long-term results. The study is…

This study is testing whether adding a drug called fasudil hydrochloride to immunotherapy helps control advanced prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. It will involve about 30 men who have already tried other treatmen…

This study is testing if adding a drug called homoharringtonine to standard hormone therapy before prostate cancer surgery is more effective. The goal is to see if this combination can better shrink or eliminate the cancer, potentially leading to better long-term outcomes. The tr…